• ​Shadow Health Records Meet New Data Privacy Laws, 363 Science 448 (2019) (with Margot E. Kaminski, Timo Minssen, and Kayte Spector-Bagdady) (non-PDF full-text here)
• Privacy in the Age of Medical Big Data, 35 Nature Medicine 37 (2019) (with I. Glenn Cohen)
• Big Data and Black-Box Medical Algorithms, 10 Science Translational Medicine eaao5333 (2018)
• Grants, 34 Berkeley Technology Law Journal 1 (2019)
• Drug Approval in a Learning Health System, 102 Minnesota Law Review 101 (2018)
• Regulating Black-Box Medicine, 116 Michigan Law Review 421 (2017)
• Risk and Resilience in Health Data Infrastructure, 16 Colorado Science and Technology Law Review 65 (2017)
• Medical Malpractice and Black-Box Medicine (chapter)  in Big Data, Health Law, and Bioethics (Effy Vayema et al., eds.) (Cambridge University Press, 2018)
• Expired Patents, Trade Secrets, and Stymied Competition, 92 Notre Dame Law Review 1611 (2017)
• Promoting Healthcare Innovation on the Demand Side, 4 Journal of Law & the Biosciences 3 (2017) (with Rebecca Eisenberg)
• Privacy and Accountability in Black-Box Medicine, 22 Michigan Telecommunications & Technology Law Review 1 (2016) (with Roger Ford)
• Regulating Secrecy, 91 Washington Law Review 1769 (2016)
• Big Data, Patents, and the Future of Medicine, 37 Cardozo Law Review 1401 (2016)
• Manufacturing Barriers to Biologics Competition and Innovation, 101 Iowa Law Review 1023 (with Arti Rai)
• Describing Black-Box Medicine, 20 Boston University Journal of Science & Technology Law 347 (2016)
• Codon influence on large-scale protein expression correlates with E. coli mRNA levels, 529 Nature 358 (2016) (with Greg Boel et al.)
• Innovation Policy Failures in the Manufacturing of Drugs (chapter) and Timing is Everything: Balancing Access and Uncertainty (section introduction) in FDA in the 21st Century: The Challenges of Regulating Drugs and New Technologies (I. Glenn Cohen & Holly Lynch, eds.) (Columbia University Press, 2015)
• Black-Box Medicine, 28 Harvard Journal of Law & Technology 419 (2015)
• Will clinical trial data disclosure reduce incentives to develop new uses of drugs?, 33 Nature Biotechnology 685 (2015) (with Timo Minssen)
• Are trade secrets delaying biosimilars?, 348 Science 188 (2015) (with Arti Rai)
• Patent Trolling—Why Bio & Pharmaceuticals Are at Risk, 17 Stanford Technology Law Review 773 (2014) (with Robin Feldman)
• Generic Entry Jujitsu: Innovation and Quality in Drug Manufacturing, 4 IP Theory 1 (2014)
• Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing, 55 Boston College Law Review 491 (2014)
• Nudging the FDA, 10 American Interest 35 (2014) (with I. Glenn Cohen)
• Models of Consent to Return of Incidental Findings in Genomic Research, 44 Hastings Center Report 22 (2014) (with Paul S. Appelbaum et al.)
• Chemotherapy drug shortages in pediatric oncology: a consensus statement, 133 Pediatrics e716 (2014) (working-group member)
• Problems of Innovation-Deficient Pharmaceutical Manufacturing, Harvard Business Review/New England Journal of Medicine Insight Center on High-Value Health Care (2013)
• Informed Consent for Return of Incidental Findings in Genomic Research, 16 Genetics in Medicine 367 (2013) (with Paul S. Appelbaum et al.)
• Legal Implications of an Ethical Duty to Search for Genetic Incidental Findings, 13 American Journal of Bioethics 48 (2013)
• Unblocked Future: Why Gene Patents Won’t Hinder Whole-Genome Sequencing and Personalized Medicine, 33 Cardozo Law Review 1601 (2012)
• Does Whole-Genome Sequencing Circumvent Gene Patents?, Bio-IT World (Dec. 10, 2012)
• Large-Scale Experimental Studies Show Unexpected Amino Acid Effects on Protein Expression and Solubility in vivo in E. coli, 1 Microbial Informatics and Experimentation 6 (2011) (with Samuel Handelman et al.)
• Am I My Son? Clones and the Modern Family, Note, 11 Columbia Science & Technology Law Review 118 (2010)
• The Deepwater Horizon Oil Spill: Potential Insurance Coverage Implications, Insurance Law Coverage Bulletin (September 2010) (with Lynn K. Neuner)
• Understanding the Physical Properties that Control Protein Crystallization by Analysis of Large-Scale Experimental Data, 27 Nature Biotechnology 51 (2009) (with Yang Chen et al.)
• Patenting Race: The Implications of Ethnic Genetic Testing, Note, 8 Columbia Science & Technology Law Review 119 (2007)
• MxA Gene Expression Analysis as an Interferon-beta Bioactivity Measurement in Patients with Multiple Sclerosis and the Identification of Antibody-Mediated Decreased Bioactivity, 7 Molecular Diagnosis 17 (2003) (with Andrew Pachner et al.)